WO2016175230A1 - 経口投与用医薬組成物 - Google Patents
経口投与用医薬組成物 Download PDFInfo
- Publication number
- WO2016175230A1 WO2016175230A1 PCT/JP2016/063151 JP2016063151W WO2016175230A1 WO 2016175230 A1 WO2016175230 A1 WO 2016175230A1 JP 2016063151 W JP2016063151 W JP 2016063151W WO 2016175230 A1 WO2016175230 A1 WO 2016175230A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- oral administration
- pharmaceutically acceptable
- compound
- acceptable salt
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Definitions
- the present invention relates to 1- ⁇ 5-[(5- ⁇ [(2R) -2-ethylpyrrolidin-1-yl] methyl ⁇ -4- [4-methoxy-3- (trifluoromethyl) phenyl] -1,
- the present invention relates to a pharmaceutical composition for oral administration comprising 3-thiazol-2-yl) carbamoyl] pyrazin-2-yl ⁇ piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof.
- the present invention relates to 1- ⁇ 5-[(5- ⁇ [(2R) -2-ethylpyrrolidin-1-yl] methyl ⁇ -4- [4-methoxy-3- (trifluoromethyl) phenyl ] -1,3-thiazol-2-yl) carbamoyl] pyrazin-2-yl ⁇ piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for oral administration comprising a cellulose derivative It is about things.
- Compound A 1- ⁇ 5-[(5- ⁇ [(2R) -2-ethylpyrrolidin-1-yl] methyl ⁇ -4- [4-methoxy-3- (trifluoromethyl) phenyl] -1,3-thiazole- 2-yl) carbamoyl] pyrazin-2-yl ⁇ piperidine-4-carboxylic acid (hereinafter sometimes referred to as Compound A) is represented by the following chemical structural formula and exhibits muscarinic M 3 receptor positive allosteric modulator activity. a bladder contractions due to muscarinic M 3 receptors is known to be useful as a preventive and / or therapeutic agent for bladder and urinary tract disease involving (Patent Document 1).
- Some drugs are not only poorly soluble, but also have a pH dependency in solubility, or a decrease in drug solubility due to properties such as gelation when contacted with water. Therefore, there is room for further improvement in order to provide a preparation with improved solubility of a poorly soluble drug and improved oral absorption.
- the present inventors examined a pharmaceutical composition comprising Compound A or a pharmaceutically acceptable salt thereof, and as a result, Compound A has a pH dependency in solubility, a solvent such as water, and the like. I knew that there was a problem of gelation on contact. Compound A has pH dependency on its solubility, especially when the pH is in the neutral region, the absorption is reduced by recrystallization or reprecipitation from the dissolved state when reaching the absorption site. There is a risk. In addition, when Compound A comes into contact with a solvent, it gels by contact with gastric juice or the like in vivo after taking, or gelation or aggregation derived from a water-soluble polymer of a solid dispersion carrier.
- an object of the present invention is to provide a pharmaceutical composition for oral administration which has improved solubility and absorption of Compound A or a pharmaceutically acceptable salt thereof having pH dependency in solubility. It is in.
- the solubility of Compound A in the acidic pH region [Japanese Pharmacopoeia Dissolution Test 1st Solution (JP1 (pH 1.2))] is about 44.1 ⁇ g / mL, and the neutral pH region [Japanese Pharmacopoeia Dissolution Test 2
- the solubility in the liquid JP2 (pH 6.8))] is about 17.8 ⁇ g / mL.
- Compound A has low solubility in both acidic pH range and neutral pH range, but it has low solubility particularly in neutral pH range. Therefore, organisms accompanying the decrease in elution rate and delay in elution in neutral pH range such as small intestine. There is concern about a decline in scientific availability (BA). Under such circumstances, the inventors of the present invention focused on improving the solubility and elution of Compound A, and as a result of intensive studies, they have completed the present invention.
- the present invention [1] 1- ⁇ 5-[(5- ⁇ [(2R) -2-ethylpyrrolidin-1-yl] methyl ⁇ -4- [4-methoxy-3- (trifluoromethyl) phenyl] -1,3 -Thiazol-2-yl) carbamoyl] pyrazin-2-yl ⁇ piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for oral administration containing a cellulose derivative, [2] The pharmaceutical composition for oral administration according to [1], wherein the cellulose derivative is hydroxypropylcellulose and / or hypromellose, [3] The pharmaceutical composition for oral administration according to [1] or [2], wherein the cellulose derivative is hydroxypropylcellulose; [4] 1- ⁇ 5-[(5- ⁇ [(2R) -2-ethylpyrrolidin-1-yl] methyl ⁇ -4- [4-methoxy-3- (trifluoromethyl)
- the pharmaceutical composition containing Compound A or a pharmaceutically acceptable salt thereof that gels when contacted with a solvent can be rapidly disintegrated and dispersed.
- FIG. 2 is a graph showing the results of a supersaturation test of the pharmaceutical composition for oral administration in Example 1.
- FIG. 2 is a graph showing the results of a supersaturation test of the pharmaceutical composition for oral administration in Example 2.
- FIG. 2 is a graph showing the results of a supersaturation test of a pharmaceutical composition for oral administration in Comparative Example 1.
- 3 is a graph showing the results of measuring dissolution rates of pharmaceutical compositions for oral administration in Examples 3 to 11.
- “maintaining a supersaturated state” means, for example, when evaluating by the Japanese Pharmacopoeia dissolution test paddle method (50 rpm, test solution is JP2 ⁇ 250 mL), Compound A in the pharmaceutical composition or a pharmaceutical product thereof
- the solubility of the salt or the elution rate of the compound A is 6 times or more of the solubility of the compound A in the crystalline state or its pharmaceutically acceptable salt or the elution rate of the compound A, and as an aspect, 7 times or more
- it is defined as a state where the solubility or the dissolution rate of Compound A is improved and maintained for 120 minutes or more.
- “improves the dissolution property” means that the dissolution rate of Compound A in water or a buffer solution increases.
- a pharmaceutical composition for example, a solid dispersion or a tablet containing a solid dispersion
- Compound A or a pharmaceutically acceptable salt thereof is converted into a Japanese Pharmacopoeia dissolution test paddle method ( When the dissolution test is carried out according to 25 rpm and the test solution is 0.03 N hydrochloric acid (900 mL), the dissolution rate of Compound A after 30 minutes is 25% or more, preferably 70% or more, more preferably 85% or more. Stipulate.
- the dissolution rate of Compound A after 15 minutes when the dissolution test is carried out according to the Japanese Pharmacopoeia dissolution test paddle method is more preferably 70% or more. Is defined as 85% or more.
- “improving the stability of Compound A or a pharmaceutically acceptable salt thereof” refers to a pharmaceutical composition for oral administration containing Compound A or a pharmaceutically acceptable salt thereof.
- “suppressing the production of a compound A or a pharmaceutically acceptable salt thereof during storage” refers to, for example, storing a pharmaceutical composition for oral administration under the following conditions, Among the related substances contained in Compound A or a pharmaceutically acceptable salt thereof contained in the pharmaceutical composition for oral administration, those having the largest percentage (peak area) (maximum related substances), or Compound A or a pharmaceutical thereof The total amount of salt analogs that are pharmaceutically acceptable is defined as a specific percentage or less.
- a pharmaceutical composition for oral administration is 40 ° C. and 75% relative humidity (hereinafter sometimes abbreviated as% RH), After being stored for 1 month under sealed conditions, it is measured by a high performance liquid chromatograph method (hereinafter sometimes abbreviated as HPLC method). Alternatively, it is measured by high performance liquid chromatography after being stored at 70 ° C. under sealed conditions for 7 days or 9 days.
- the percentage of the maximum analog of compound A or a pharmaceutically acceptable salt thereof in a pharmaceutical composition for oral administration is defined as 2.0% or less as an embodiment and 0.9% or less as an embodiment. To do.
- the maximum analog of compound A or a pharmaceutically acceptable salt thereof is specifically determined by measuring the peak area of each analog included in the pharmaceutical composition for oral administration by HPLC, It is defined as the substance that has the highest ratio of the pharmaceutically acceptable salt and its related substances to the total peak area.
- the total amount of related substances of Compound A or a pharmaceutically acceptable salt thereof is measured by, for example, HPLC after storing a pharmaceutical composition for oral administration for 1 month under sealed conditions of 40 ° C. and 75% RH. Is done. It is defined that the total amount of related substances of Compound A or a pharmaceutically acceptable salt thereof in a pharmaceutical composition for oral administration is, for example, 3.0% or less, and in one embodiment, 1.0% or less.
- the conditions of 2 months, 3 months, or 6 months under the same conditions can also be adopted. Moreover, it can select and set suitably from the conditions from 1 month to 24 months or 36 months on 25 degreeC and 60% RH open
- “suppressing a change in the dissolution rate of Compound A from a pharmaceutical composition for oral administration” means more specifically reducing a change in the dissolution rate of Compound A from a pharmaceutical composition for oral administration. Specifically, this means that the difference between the dissolution rate after storage and the dissolution rate before storage is reduced.
- a pharmaceutical composition for oral administration is stored for 6 days under an open condition of 25 ° C. and 75% RH, and then a dissolution test is performed according to the Japanese Pharmacopoeia dissolution test paddle method (50 rpm, test solution is 900 mL of 0.03 N hydrochloric acid).
- the change in elution rate after 30 minutes is 10% or less before and after storage, and in some embodiments, the change in elution rate after 15 minutes before and after storage It means 10% or less.
- the pharmaceutical composition for oral administration was stored for 21 days under 25 ° C. and 75% RH open conditions, and then the dissolution test was conducted according to the Japanese Pharmacopoeia dissolution test paddle method (50 rpm, test solution was 900 mL of 0.03 normal hydrochloric acid). This means that the change in dissolution rate after 30 minutes (difference between dissolution rate after storage and dissolution rate before storage) is 10% or less before and after storage.
- composition for oral administration of the present invention is described in detail below.
- Compound A or a pharmaceutically acceptable salt thereof used in the present invention can be easily obtained by, for example, the method described in Patent Document 1 or production according thereto.
- Compound A can form a pharmaceutically acceptable salt with an acid or base, in addition to the free form.
- salts include acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid.
- Organic acids such as acid, fumaric acid, maleic acid, lactic acid, malic acid, mandelic acid, tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, amino acids
- Acid addition salts salts with inorganic bases such as sodium, potassium, magnesium, calcium and aluminum
- salts with organic bases such as methylamine, ethylamine and ethanolamine
- various amino acids or amino acids such as acetylleucine, lysine and ornithine Examples thereof include salts with derivatives and ammonium salts. These salts can be produced by conventional methods.
- the appropriate daily dose is about 0.001 to 100 mg / kg per body weight, which is administered once or divided into 2 to 4 times.
- the dose is appropriately determined according to individual cases in consideration of symptoms, age, sex, and the like.
- the blending ratio of Compound A or a pharmaceutically acceptable salt thereof is, for example, 1% by weight or more and 70% by weight or less as a certain aspect, 5% by weight or more and 70% by weight or less as a certain aspect per pharmaceutical composition, As an aspect, it is 5 to 50 weight%, as an aspect, 5 to 20 weight%, and as an aspect, 10 to 15 weight%.
- the cellulose derivative used in the present invention is not particularly limited as long as the solubility of Compound A is 6 or more times the solubility of Compound A in a crystalline state or a pharmaceutically acceptable salt thereof.
- HPC hydroxypropyl cellulose
- examples of hypromellose include TC-5E and TC-5R (manufactured by Shin-Etsu Chemical Co., Ltd.).
- examples of the HPC include HPC-L and HPC-SL (manufactured by Nippon Soda). These may be used alone or in combination as appropriate.
- the blending ratio of the cellulose derivative is not particularly limited as long as the solubility of the compound A is an amount that is 6 times or more the solubility of the crystalline compound A or a pharmaceutically acceptable salt thereof.
- the weight of the pharmaceutical composition in some embodiments, 0.1 wt% or more and 75 wt% or less, in some embodiments, 0.5 wt% or more and 35 wt% or less, and in some embodiments, 1 wt% or more and 10 wt% or less. % By weight or less.
- Compound A or a pharmaceutically acceptable salt thereof as an aspect, 10 wt% or more and 1000 wt% or less, as an aspect 20 wt% or more and 500 wt% or less, 30% by weight or more and 40% by weight or less, and in one embodiment, 35% by weight.
- the foamable substance used in the present invention is not particularly limited as long as it can foam in water, buffer solution, or gastric juice.
- Examples of the foamable substance used in the present invention include sodium bicarbonate.
- the blending ratio of the foamable substance is not particularly limited as long as it is an amount that foams in liquids such as gastric juice, water, and buffer solution.
- 0.1 wt% or more and 90 wt% or less as an embodiment 1 wt% or more and 60 wt% or less, as an embodiment 1 wt% or more and 40 wt%
- it is 2 to 30 weight%.
- Compound A or a pharmaceutically acceptable salt thereof as an aspect, 10 wt% or more and 300 wt% or less, as an aspect 20 wt% or more and 250 wt% or less, 30% by weight or more and 250% by weight or less, and in some embodiments, 30% by weight or more and 200% by weight or less.
- Ingredients that aid the disintegration used in the present invention are water-insoluble substances or water-swellable substances that improve the disintegration of the pharmaceutical composition for oral administration of the present invention and / or improve the dissolution property of Compound A.
- crystalline cellulose, calcium hydrogen phosphate hydrate, sodium starch glycolate, low-substituted hydroxypropyl cellulose, croscarmellose sodium and the like can be mentioned.
- Preferred is crystalline cellulose, low-substituted hydroxypropylcellulose, croscarmellose sodium, more preferred is crystalline cellulose, croscarmellose sodium, and still more preferred is croscarmellose sodium.
- One or two or more components that assist the disintegration can be used in appropriate combination.
- the mixing ratio of the component that helps disintegration is not particularly limited as long as it is an amount that can improve the disintegration property of the pharmaceutical composition for oral administration of the present invention and / or can improve the dissolution property of Compound A.
- the weight of a pharmaceutical composition it is 1 to 99 weight%, and as an aspect, it is 5 to 80 weight%.
- the weight of Compound A or a pharmaceutically acceptable salt thereof as an aspect, 10 wt% or more and 1000 wt% or less, as an aspect 35 wt% or more and 600 wt% or less, It is 50 weight% or more and 600 weight% or less.
- the blending ratio of the foaming substance and the component that aids disintegration is an amount that can improve the stability of Compound A or a pharmaceutically acceptable salt thereof and / or an amount that can improve the elution stability of Compound A. If there is, there is no particular limitation.
- 10 wt% or more and 60 wt% or less as an embodiment, 15 wt% or more and 50 wt% or less, and as an embodiment, 25 wt% or more and 40 wt% or less is there.
- compositions for oral administration of the present invention various pharmaceutical additives are appropriately used and formulated as long as the desired effect of the present invention is achieved.
- a pharmaceutical additive is not particularly limited as long as it is pharmaceutically acceptable and pharmacologically acceptable.
- excipients, binders, acidulants, sweeteners, fragrances, colorants, buffers, antioxidants, surfactants and the like are used.
- excipients examples include starch, pregelatinized starch, dextrin, sodium carboxymethylcellulose, gum arabic, dextrin, pullulan, light anhydrous silicic acid, synthetic aluminum silicate, magnesium aluminate metasilicate, and the like.
- binder examples include gum arabic and hydroxyethyl cellulose.
- sour agent examples include citric acid, tartaric acid, malic acid and the like.
- sweetening agents include saccharin sodium, glycyrrhizic acid, aspartame, stevia, thaumatin and the like.
- fragrances include lemon, lime, orange and menthol.
- Examples of the colorant include food yellow No. 4, No. 5, food red No. 3, No. 102, food blue No. 3, and the like.
- buffer examples include citric acid, succinic acid, fumaric acid, tartaric acid, ascorbic acid or salts thereof, glutamic acid, glutamine, glycine, aspartic acid, alanine, arginine or salts thereof, magnesium oxide, zinc oxide, magnesium hydroxide, Examples thereof include phosphoric acid, boric acid, and salts thereof.
- antioxidants examples include ascorbic acid, dibutylhydroxytoluene, propyl gallate and the like.
- surfactant examples include polysorbate 80, sodium lauryl sulfate, polyoxyethylene hydrogenated castor oil, and the like.
- These pharmaceutical additives can be appropriately added in an appropriate amount by combining one or more kinds.
- any pharmaceutical additive is used in an amount within the range in which the desired effect of the present invention is achieved.
- the pharmaceutical composition for oral administration of the present invention can be produced by appropriately combining methods known per se.
- Solid Dispersion Preparation Step The solid dispersion of the present invention, which is an embodiment of the pharmaceutical composition for oral administration of the present invention, comprises Compound A or a pharmaceutically acceptable salt thereof, and a cellulose derivative. After dissolving and / or suspending in a pharmaceutically acceptable solvent, the solvent can be distilled off for production.
- the pharmaceutically acceptable solvent used in the present invention is not particularly limited as long as it can dissolve and / or suspend the cellulose derivative and Compound A or a pharmaceutically acceptable salt thereof.
- Ketones such as acetone, alcohols such as methanol, ethanol, and propanol, dichloromethane, or a mixed solvent thereof and water.
- One or two or more pharmaceutically acceptable solvents can be appropriately mixed and used.
- a solution in which Compound A or a pharmaceutically acceptable salt thereof and a water-soluble polymer substance are dissolved and / or suspended is used.
- a spray-drying method, a reduced pressure drying method, a ventilation drying method etc. are mentioned,
- a spray-drying method is mentioned.
- the step is not particularly limited as long as it is a method capable of granulating a drug or the like.
- a production method and apparatus for example, fluidized bed granulation method, melt granulation method, high speed stirring granulation method, crushing (pulverization) granulation method, extrusion granulation method, rolling granulation method, spray granulation method, Examples thereof include dry granulation methods and apparatuses used by these methods.
- One embodiment is a dry granulation method / apparatus.
- a binder used for a granulation method it can be used 1 type or in combination of 2 or more types as appropriate. It can also be dried after granulation.
- the drying method is not particularly limited as long as it is a pharmaceutically drying method.
- the granulated product prepared as described above can be made into various preparations such as tablets, capsules, powders, granules, and dry syrup.
- the pharmaceutical composition for oral administration of the present invention is a tablet.
- Molding step There are no particular limitations on the apparatus and means of the step as long as it is a method for molding the pharmaceutical composition for oral administration of the present invention.
- the drug in the present invention or the solid dispersion of the present invention is mixed with an appropriate pharmaceutical additive and then directly compressed to form a tablet, granulated and further lubricated.
- Examples thereof include a method of compression-molding after mixing the agent to produce a tablet.
- Examples of the tableting device include a rotary tableting machine and an oil press. Tableting conditions such as tableting pressure are not particularly limited as long as the tableting pressure can produce a tablet.
- the hardness of the tableted product is not particularly limited as long as it does not break during the manufacturing process or the distribution process. An example is 40 to 500N.
- the method is not particularly limited as long as it is usually a pharmaceutically coating method. Examples thereof include pan coating and dip coating.
- the coating rate is not particularly limited as long as it is a rate for forming a film. For example, it is 1 to 10% by weight relative to the weight of the whole preparation.
- the method is not particularly limited as long as it can be usually pharmaceutically dried.
- the drying conditions are not particularly limited as long as they are appropriately set in consideration of, for example, the stability of the preparation.
- compositions for oral administration of the present invention for example, bladder contractions due to muscarinic M 3 receptor is used as a prophylactic and / or therapeutic pharmaceutical compositions of the bladder and urinary tract diseases involved.
- the method for producing the pharmaceutical composition for oral administration of the present invention includes a method for producing the pharmaceutical composition by appropriately combining methods known per se in addition to the method described above.
- the present invention includes a method for improving the dissolution property with an effervescent substance in a pharmaceutical composition for oral administration containing Compound A or a pharmaceutically acceptable salt thereof and a cellulose derivative.
- a pharmaceutical composition for oral administration containing Compound A or a pharmaceutically acceptable salt thereof and a cellulose derivative used in the dissolution improvement method of the present invention
- the description in the pharmaceutical composition for oral administration of the present invention can be applied as it is. it can.
- the dissolution improvement method of the present invention in providing a pharmaceutical composition for oral administration containing Compound A or a pharmaceutically acceptable salt thereof and a cellulose derivative, compounding the foamable substance, The elution of A can be improved.
- a compounding ratio, the said description in the pharmaceutical composition for oral administration of this invention and its manufacturing method is applicable as it is.
- the present invention includes the use of an effervescent substance for improving dissolution in a pharmaceutical composition for oral administration containing Compound A or a pharmaceutically acceptable salt thereof and a cellulose derivative.
- the “oral administration pharmaceutical composition containing compound A or a pharmaceutically acceptable salt thereof and a cellulose derivative” and “foamable substance” used in the present invention are the pharmaceutical composition for oral administration of the present invention.
- the said description in a thing can be applied as it is.
- the use of the foamable substance of the present invention can improve dissolution when providing a pharmaceutical composition for oral administration containing Compound A or a pharmaceutically acceptable salt thereof and a cellulose derivative.
- About the compounding quantity of each component in the use of this invention, a compounding method, the said description in the pharmaceutical composition for oral administration of this invention and its manufacturing method is applicable as it is.
- Example 1 According to the formulation in Table 1, 0.5 g of Compound A and 1.5 g of hypromellose (TC5E, manufactured by Shin-Etsu Chemical Co., Ltd., the same unless otherwise stated) were dissolved in a mixture of dichloromethane and methanol to prepare a spray solution. The spray solution was spray-dried and dried to obtain a pharmaceutical composition (solid dispersion) for oral administration of the present invention.
- a pharmaceutical composition solid dispersion
- Example 2 According to the formulation in Table 1, 0.5 g of Compound A and 1.5 g of hydroxypropylcellulose (HPC-SL, manufactured by Nippon Soda Co., Ltd., the same unless otherwise specified) were dissolved in a mixture of dichloromethane and methanol to prepare a spray solution. The spray solution was spray-dried and dried to obtain a pharmaceutical composition (solid dispersion) for oral administration of the present invention.
- HPC-SL hydroxypropylcellulose
- Comparative Example 1 According to the formulation shown in Table 1, 0.5 g of Compound A and 1.5 g of polyvinylpyrrolidone (Kollidon 30, manufactured by BASF) were dissolved in a mixed solution of dichloromethane and methanol to prepare a spray solution. After spray-drying and drying the spray solution, a comparative pharmaceutical composition for oral administration (solid dispersion) was obtained.
- Example 3 Preparation of solid dispersion Compound A (250.0 g) and hydroxypropylcellulose (87.5 g) were dissolved in a mixed solution of dichloromethane and methanol to prepare a spray solution. The spray solution was spray-dried and dried to obtain a pharmaceutical composition (solid dispersion) for oral administration of the present invention.
- Example 4 Preparation of solid dispersion Compound A 1200 g and hydroxypropylcellulose 420 g were dissolved in a mixture of dichloromethane and methanol to prepare a spray solution. The spray solution was spray-dried and dried to obtain a pharmaceutical composition (solid dispersion) for oral administration of the present invention.
- Example 5 675 mg of the solid dispersion produced in Example 3 (1), 375 mg of sodium bicarbonate, 1912.5 mg of crystalline cellulose, 750 mg of sodium starch glycolate, 37.5 mg of magnesium stearate were mixed, and 750 mg was weighed and compressed. Molding was performed to obtain the pharmaceutical composition (tablet) for oral administration of the present invention.
- the prescription is shown in Table 1.
- Example 6 675 mg of the solid dispersion produced in Example 3 (1), sodium bicarbonate 187.5 mg, crystalline cellulose 2100 mg, sodium starch glycolate 750 mg, magnesium stearate 37.5 mg were mixed, and 750 mg was weighed and compressed. Molding was performed to obtain the pharmaceutical composition (tablet) for oral administration of the present invention.
- the formulation is shown in Table 2.
- Example 7 675 mg of solid dispersion produced in Example 3 (1), 750 mg of sodium hydrogen carbonate, calcium hydrogen phosphate hydrate (Rika, manufactured by Kyowa Chemical Industry) 1537.5 mg, sodium starch glycolate 750 mg, magnesium stearate 37.5 mg was mixed, 750 mg was weighed and compression molded to obtain a pharmaceutical composition (tablet) for oral administration of the present invention.
- the formulation is shown in Table 2.
- Example 8 Solid dispersion 1350 mg produced in Example 4 (1), sodium bicarbonate 1500 mg, crystalline cellulose 3131.25 mg, low substituted hydroxypropylcellulose (L-HPC LH11, manufactured by Shin-Etsu Chemical Co., Ltd.) 1500 mg, magnesium stearate 18.75 mg was mixed, 750 mg was weighed and compression molded to obtain a pharmaceutical composition (tablet) for oral administration of the present invention.
- the formulation is shown in Table 2.
- Example 9 2700 mg of the solid dispersion produced in Example 4 (1), 3000 mg of sodium bicarbonate, 6262.5 mg of crystalline cellulose, 3000 mg of croscarmellose sodium (Kickolate ND-2HS, manufactured by Nichirin Chemical), 37.5 mg of magnesium stearate are mixed Of these, 750 mg was weighed and compression molded to obtain the pharmaceutical composition (tablet) for oral administration of the present invention.
- the formulation is shown in Table 2.
- Example 10 Preparation of solid dispersion Compound A (2.0 kg) and hydroxypropylcellulose (0.7 kg) were dissolved in a mixed solution of dichloromethane and methanol to prepare a spray solution. The spray solution was spray-dried and dried to obtain a pharmaceutical composition (solid dispersion) for oral administration of the present invention.
- Example 11 378.0 g of a solid dispersion produced under the same conditions as in Example 10 (1), 420.0 g of sodium hydrogen carbonate, 876.75 g of crystalline cellulose, and 420.0 g of sodium starch glycolate were mixed, and dry granulation was performed. Thereafter, 5.25 g of magnesium stearate was mixed and compression molded. Thereafter, 63 g of a film coating agent was film coated to obtain a pharmaceutical composition (tablet) for oral administration of the present invention. The formulation is shown in Table 2.
- Example 12 2700 mg of the solid dispersion produced in Example 4 (1), 750 mg of sodium bicarbonate, 8512.5 mg of crystalline cellulose, 3000 mg of croscarmellose sodium, 37.5 mg of magnesium stearate were mixed, 750 mg was weighed and compressed. Molding was performed to obtain the pharmaceutical composition (tablet) for oral administration of the present invention.
- the formulation is shown in Table 3.
- Example 13 Solid dispersion 1350 mg produced in Example 4 (1), sodium bicarbonate 750 mg, crystalline cellulose 4256.25 mg, croscarmellose sodium 1125 mg, magnesium stearate 18.75 mg were mixed, and 750 mg was weighed and compressed. Molding was performed to obtain the pharmaceutical composition (tablet) for oral administration of the present invention.
- the formulation is shown in Table 3.
- Example 14 2700 mg of the solid dispersion produced in Example 4 (1), 1500 mg of sodium bicarbonate, 7762.5 mg of crystalline cellulose, 3000 mg of croscarmellose sodium, and 37.5 mg of magnesium stearate were mixed, and 750 mg was weighed and compressed. Molding was performed to obtain the pharmaceutical composition (tablet) for oral administration of the present invention.
- the formulation is shown in Table 3.
- Example 15 Solid dispersion 1350 mg produced in Example 4 (1), sodium bicarbonate 937.5 mg, crystalline cellulose 4256.25 mg, croscarmellose sodium 937.5 mg, magnesium stearate 18.75 mg were mixed, of which 750 mg was weighed and compressed. Molding was performed to obtain the pharmaceutical composition (tablet) for oral administration of the present invention.
- the formulation is shown in Table 3.
- Example 16 1350 mg of the solid dispersion produced in Example 4 (1), 1125 mg of sodium bicarbonate, 4256.25 mg of crystalline cellulose, 750 mg of croscarmellose sodium and 18.75 mg of magnesium stearate are mixed, and 750 mg is weighed and compressed. Molding was performed to obtain the pharmaceutical composition (tablet) for oral administration of the present invention.
- the formulation is shown in Table 3.
- Example 17 Solid dispersion 1350 mg produced in Example 4 (1), sodium bicarbonate 1125 mg, crystalline cellulose 3881.25 mg, croscarmellose sodium 1125 mg, magnesium stearate 18.75 mg were mixed, and 750 mg was weighed and compressed. Molding was performed to obtain the pharmaceutical composition (tablet) for oral administration of the present invention.
- the formulation is shown in Table 3.
- Example 18 2700 mg of the solid dispersion produced in Example 4 (1), 3000 mg of sodium bicarbonate, 8512.5 mg of crystalline cellulose, 750 mg of croscarmellose sodium, and 37.5 mg of magnesium stearate were mixed, and 750 mg was weighed and compressed. Molding was performed to obtain the pharmaceutical composition (tablet) for oral administration of the present invention.
- the formulation is shown in Table 3.
- Example 19 2700 mg of the solid dispersion produced in Example 4 (1), 3000 mg of sodium bicarbonate, 7762.5 mg of crystalline cellulose, 1500 mg of croscarmellose sodium and 37.5 mg of magnesium stearate were mixed, and 750 mg was weighed and compressed. Molding was performed to obtain the pharmaceutical composition (tablet) for oral administration of the present invention.
- the formulation is shown in Table 3.
- Example 20 Solid dispersion 2700 mg produced in Example 4 (1), sodium bicarbonate 4500 mg, crystalline cellulose 7012.5 mg, croscarmellose sodium 750 mg, magnesium stearate 37.5 mg were mixed, and 750 mg was weighed and compressed. Molding was performed to obtain the pharmaceutical composition (tablet) for oral administration of the present invention.
- the formulation is shown in Table 3.
- Example 21 2700 mg of the solid dispersion produced in Example 4 (1), 750 mg of sodium bicarbonate, 10012.5 mg of crystalline cellulose, 1500 mg of croscarmellose sodium and 37.5 mg of magnesium stearate were mixed, and 750 mg was weighed and compressed. Molding was performed to obtain the pharmaceutical composition (tablet) for oral administration of the present invention.
- the formulation is shown in Table 3.
- Example 22 2700 mg of the solid dispersion produced in Example 4 (1), 1500 mg of sodium bicarbonate, 9262.5 mg of crystalline cellulose, 1500 mg of croscarmellose sodium and 37.5 mg of magnesium stearate were mixed, and 750 mg was weighed and compression molded.
- the pharmaceutical composition (tablet) for oral administration of the present invention was obtained.
- the formulation is shown in Table 3.
- Example 3 Measurement of Related Substances
- the pharmaceutical compositions (tablets) for oral administration of Examples 4, 8 and 9 were placed in aluminum bags and stored at 70 ° C. for 7 days while being sealed.
- Related substances before and after storage were measured by HPLC.
- the related substances were measured under the following conditions: -As the HPLC column, Inertsil C8-3, particle diameter 3 ⁇ m, 4.6 mm (inner diameter) ⁇ 15 cm (manufactured by GL Sciences) or its equivalent was used and maintained at a constant temperature around 40 ° C.
- As the mobile phase A a pH 2.0 perchloric acid solution was used.
- -As mobile phase B acetonitrile was used.
- Example 4 Dissolution Stability
- the pharmaceutical compositions for oral administration of the present invention of Examples 8 and 9 were stored for 6 days under 25 ° C. and 75% RH open conditions.
- the dissolution before and after storage was evaluated according to the Japanese Pharmacopoeia dissolution test paddle method (50 rpm).
- the test solution was 900 mL of 0.03 normal hydrochloric acid, and the elution rate of Compound A 30 minutes after the start of the test was measured by ultraviolet spectroscopy (UV method (measurement wavelength: 343 nm)).
- UV method ultraviolet spectroscopy
- Example 5 Dissolution stability
- the pharmaceutical compositions for oral administration of the present invention of Examples 12 to 22 were stored for 6 days at 25 ° C. and 75% RH open conditions.
- the dissolution before and after storage was evaluated according to the Japanese Pharmacopoeia dissolution test paddle method (50 rpm).
- the test solution was 900 mL of 0.03 normal hydrochloric acid, and the elution rate of Compound A 15 minutes after the start of the test was measured by ultraviolet spectroscopy (UV method (measurement wavelength: 343 nm)).
- UV method ultraviolet spectroscopy
- Example 23 A spray solution was prepared by dissolving 50 g of Compound A and 15 g of hydroxypropylcellulose in a mixed solution of dichloromethane and methanol. The spray solution was spray-dried and dried to obtain a pharmaceutical composition (solid dispersion) for oral administration of the present invention.
- Example 24 A spray solution was prepared by dissolving 500 g of Compound A and 500 g of hydroxypropylcellulose in a mixed solution of dichloromethane and methanol. The spray solution was spray-dried and dried to obtain a pharmaceutical composition (solid dispersion) for oral administration of the present invention.
- Example 25 A spray solution was prepared by dissolving 50 g of compound A and 25 g of hypromellose in a mixed solution of dichloromethane and methanol. The spray solution was spray-dried and dried to obtain a pharmaceutical composition (solid dispersion) for oral administration of the present invention.
- composition (solid dispersion) obtained in Examples 23 to 25 was orally administered to male beagle dogs in an amount of 100 mg of Compound A or an equivalent amount of 500 mg, respectively. After administration, blood was collected over time, and the concentration of Compound A in plasma obtained by centrifugation was measured. Dogs were fasted at least 16 hours before the scheduled administration time. In addition, 30 minutes before administration, 30 minutes and 90 minutes after administration, pentagastrin was intramuscularly administered to the buttocks, and the gastric pH was acidified to carry out the test.
- the results are shown in Table 8. As a result, it was found that the pharmaceutical compositions (solid dispersions) of Examples 23 and 24 had a good dose proportionality.
- the pharmaceutical composition for oral administration of the present invention it is possible to rapidly disintegrate and disperse the pharmaceutical composition containing Compound A having pH dependency or a pharmaceutically acceptable salt thereof.
- this invention was demonstrated along the specific aspect, the deformation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
詳細には、本発明は、1-{5-[(5-{[(2R)-2-エチルピロリジン-1-イル]メチル}-4-[4-メトキシ-3-(トリフルオロメチル)フェニル]-1,3-チアゾール-2-イル)カルバモイル]ピラジン-2-イル}ピペリジン-4-カルボン酸又はその製薬学的に許容される塩、及びセルロース誘導体を含有してなる経口投与用医薬組成物に関するものである。
従って、難溶性薬物の溶出性を改善し、かつ経口吸収性を改善した製剤を提供するには、更に改善の余地がある。
化合物Aが、その溶解性にpH依存性を有し、特にpHが中性領域で溶解性が低くなることについては、吸収部位へ到達時に溶解状態から再結晶化、或いは再析出によって吸収が低下するおそれがある。
また、化合物Aが溶媒と接触するとゲル化することについては、服用後に生体内で胃液等と接触することにより薬物がゲル化、或いは固体分散体担体の水溶性高分子由来のゲル化・凝集により、溶出が遅延し吸収低下のおそれがある。
従って、化合物A又はその製薬学的に許容される塩を含む医薬組成物を提供する際には、化合物A又はその製薬学的に許容される塩がゲル化する前に医薬組成物が崩壊し、溶出性に優れた医薬組成物が望まれる。
すなわち、本発明の目的は、溶解性にpH依存性を有する化合物A又はその製薬学的に許容される塩の溶解性改善、及び吸収性改善されてなる経口投与用医薬組成物を提供することにある。
かかる状況下、本発明者らは、化合物Aの溶解性改善、及び溶出性改善に着目して、鋭意検討を行った結果、本発明を完成させるに至った。
[1]1-{5-[(5-{[(2R)-2-エチルピロリジン-1-イル]メチル}-4-[4-メトキシ-3-(トリフルオロメチル)フェニル]-1,3-チアゾール-2-イル)カルバモイル]ピラジン-2-イル}ピペリジン-4-カルボン酸又はその製薬学的に許容される塩、及びセルロース誘導体を含有する経口投与用医薬組成物、
[2]セルロース誘導体が、ヒドロキシプロピルセルロース、及び/又はヒプロメロースである、[1]の経口投与用医薬組成物、
[3]セルロース誘導体が、ヒドロキシプロピルセルロースである、[1]又は[2]の経口投与用医薬組成物、
[4]1-{5-[(5-{[(2R)-2-エチルピロリジン-1-イル]メチル}-4-[4-メトキシ-3-(トリフルオロメチル)フェニル]-1,3-チアゾール-2-イル)カルバモイル]ピラジン-2-イル}ピペリジン-4-カルボン酸又はその製薬学的に許容される塩、及びセルロース誘導体が、固体分散体を形成する、[1]~[3]のいずれかの経口投与用医薬組成物、
[5]更に発泡性物質を含有する、[1]~[4]のいずれかの経口投与用医薬組成物、
[6]発泡性物質が、炭酸水素ナトリウムである、[5]の経口投与用医薬組成物、
[7]更に崩壊を助ける成分を含む、[1]~[6]のいずれかの経口投与用医薬組成物、
[8]崩壊を助ける成分が、結晶セルロース、リン酸水素カルシウム水和物、デンプングリコール酸ナトリウム、低置換度ヒドロキシプロピルセルロース、及びクロスカルメロースナトリウムからなる群より選択される1種又は2種以上である、[7]の経口投与用医薬組成物、
[9]崩壊を助ける成分が、結晶セルロース、低置換度ヒドロキシプロピルセルロース、及びクロスカルメロースナトリウムからなる群より選択される1種又は2種以上である、[7]又は[8]の経口投与用医薬組成物、
[10]崩壊を助ける成分が、結晶セルロース、及び/又はクロスカルメロースナトリウムである、[7]~[9]のいずれかの経口投与用医薬組成物、
[11]崩壊を助ける成分が、クロスカルメロースナトリウムである、[7]~[10]のいずれかの経口投与用医薬組成物、
[12]セルロース誘導体が、1-{5-[(5-{[(2R)-2-エチルピロリジン-1-イル]メチル}-4-[4-メトキシ-3-(トリフルオロメチル)フェニル]-1,3-チアゾール-2-イル)カルバモイル]ピラジン-2-イル}ピペリジン-4-カルボン酸又はその製薬学的に許容される塩の重量に対して10重量%以上1000重量%以下である、[1]~[11]のいずれかの経口投与用医薬組成物、
[13]経口投与用医薬組成物が、錠剤である、[1]~[12]のいずれかの経口投与用医薬組成物、
[14]経口投与用医薬組成物が、ムスカリンM3受容体による膀胱収縮が関与する膀胱・尿路系疾患の予防用及び/又は治療用医薬組成物である、[1]~[13]のいずれかの経口投与用医薬組成物、
[15]1-{5-[(5-{[(2R)-2-エチルピロリジン-1-イル]メチル}-4-[4-メトキシ-3-(トリフルオロメチル)フェニル]-1,3-チアゾール-2-イル)カルバモイル]ピラジン-2-イル}ピペリジン-4-カルボン酸又はその製薬学的に許容される塩、及びセルロース誘導体を含有する経口投与用医薬組成物において、発泡性物質による溶出性改善方法、
[16]1-{5-[(5-{[(2R)-2-エチルピロリジン-1-イル]メチル}-4-[4-メトキシ-3-(トリフルオロメチル)フェニル]-1,3-チアゾール-2-イル)カルバモイル]ピラジン-2-イル}ピペリジン-4-カルボン酸又はその製薬学的に許容される塩、及びセルロース誘導体を含有する経口投与用医薬組成物において、溶出性改善のための発泡性物質の使用
を提供するものである。
本明細書において、「過飽和状態を維持」とは、例えば、日本薬局方溶出試験パドル法(50rpm、試験液はJP2・250mL)で評価するとき、前記医薬組成物における化合物A又はその製薬学的に許容される塩の溶解性又は化合物Aの溶出率が結晶状態の化合物A又はその製薬学的に許容される塩の溶解性又は化合物Aの溶出率の6倍以上、ある態様として7倍以上で、かつ、溶解性又は化合物Aの溶出率を改善した状態で120分以上維持する状態であることと規定する。
経口投与用医薬組成物中の化合物A又はその製薬学的に許容される塩の最大類縁物質の百分率は、ある態様として2.0%以下、ある態様として0.9%以下であることと規定する。化合物A又はその製薬学的に許容される塩の最大類縁物質は、具体的には、経口投与用医薬組成物に含まれる各類縁物質のピーク面積をHPLC法により測定し、化合物A又はその製薬学的に許容される塩及びその類縁物質の総ピーク面積に対する割合が最も大きい物質として規定する。
本発明に用いられる化合物A又はその製薬学的に許容される塩は、例えば特許文献1に記載の方法、或いはそれに準じて製造することにより容易に入手可能である。
これらの塩は常法により製造できる。
化合物A又はその製薬学的に許容される塩の配合割合は、例えば、医薬組成物あたり、ある態様としては1重量%以上70重量%以下、ある態様としては5重量%以上70重量%以下、ある態様としては5重量%以上50重量%以下、ある態様としては5重量%以上20重量%以下、ある態様としては10重量%以上15重量%以下である。
これらは1種または2種以上適宜配合して使用することもできる。
本発明に用いられる発泡性物質としては、例えば、炭酸水素ナトリウム等が挙げられる。
例えば、結晶セルロース、リン酸水素カルシウム水和物、デンプングリコール酸ナトリウム、低置換度ヒドロキシプロピルセルロース、クロスカルメロースナトリウム等が挙げられる。好ましくは、結晶セルロース、低置換度ヒドロキシプロピルセルロース、クロスカルメロースナトリウム、更に好ましくは、結晶セルロース、クロスカルメロースナトリウム、更に好ましくは、クロスカルメロースナトリウムである。
崩壊を助ける成分は、1種又は2種以上適宜組み合わせて使用可能である。
配合割合については、いずれの医薬品添加物についても、本発明の所望の効果が達成される範囲内の量で使用される。
本発明の経口投与用医薬組成物は、自体公知の方法を適宜組合せて、製造することができる。
本発明の経口投与用医薬組成物の一態様である、本発明の固体分散体は、化合物A又はその製薬学的に許容される塩と、セルロース誘導体とを、製薬学的に許容される溶媒に溶解及び/又は懸濁した後、当該溶媒を留去し製造することができる。
該工程としては、薬物等を造粒できる方法であれば、装置、手段とも特に制限されない。
製造方法、装置として、例えば、流動層造粒法、溶融造粒法、高速攪拌造粒法、解砕(粉砕)造粒法、押出造粒法、転動造粒法、噴霧造粒法、乾式造粒法あるいはそれらの方法により用いられる装置等が挙げられる。ある態様として乾式造粒法・装置である。
造粒後に乾燥することも出来る。乾燥方法は、通常製薬学的に乾燥する方法であれば特に制限されない。
上記のように調製された造粒物を、錠剤、カプセル剤、散剤、顆粒剤及びドライシロップ等の各種製剤とすることができる。ある態様では、本発明の経口投与用医薬組成物は錠剤である。
該工程としては、本発明の経口投与用医薬組成物を成形する方法であれば、装置、手段とも特に制限されない。例えば、造粒・乾燥工程を行わず、本発明における薬物、あるいは、本発明の固体分散体を、適当な医薬品添加物と混合後に直接圧縮成形し錠剤を製する方法、造粒し更に滑沢剤を混合した後に圧縮成形し錠剤を製する方法等が挙げられる。
打錠圧等の打錠条件としては、錠剤を製造できる打錠圧であれば特に制限されない。
打錠品の硬度は、製造工程中乃至流通過程等で破損しない程度の硬度であれば特に制限されない。例えば、40~500Nが挙げられる。
打錠後に錠剤表面にフィルムコーティングを施してもよい。
方法としては、通常製薬学的にコーティングする方法であれば特に制限されない。例えば、パンコーティング、ディップコーティング等が挙げられる。
コーティング率は、フィルムを形成する率であれば特に制限されない。例えば、製剤全体の重量に対して、1重量%~10重量%等である。
本発明の経口投与用医薬組成物の製造方法としては、上記記載の方法の他に、自体公知の方法を適宜組合せて、製造する方法をも包含する。
本発明の溶出性改善方法で用いる「化合物A又はその製薬学的に許容される塩」、及び「セルロース誘導体」については、本発明の経口投与用医薬組成物における当該説明をそのまま適用することができる。
本発明の溶出性改善方法では、化合物A又はその製薬学的に許容される塩、及びセルロース誘導体を含有する経口投与用医薬組成物を提供するにあたり、前記発泡性物質を配合することにより、化合物Aの溶出性を改善することができる。
本発明の溶出性改善方法における各成分の配合量、配合割合等については、本発明の経口投与用医薬組成物及びその製造方法における当該説明をそのまま適用することができる。
本発明で使用される「化合物A又はその製薬学的に許容される塩、及びセルロース誘導体を含有する経口投与用医薬組成物」、「発泡性物質」については、本発明の経口投与用医薬組成物における当該説明をそのまま適用することができる。
本発明の発泡性物質の使用では、化合物A又はその製薬学的に許容される塩、及びセルロース誘導体を含有する経口投与用医薬組成物を提供するにあたり、溶出性を改善することができる。
本発明の使用における各成分の配合量、配合方法等については、本発明の経口投与用医薬組成物及びその製造方法における当該説明をそのまま適用することができる。
以下、実施例、及び試験例を挙げて、本発明を更に詳細に説明するが、本発明はこれらにより限定解釈されるものではない。
表1の処方に従って、化合物A 0.5 g、ヒプロメロース(TC5E、信越化学工業製、以下記載ない場合同じ)1.5 gを、ジクロロメタンとメタノールとの混液に溶解し噴霧液を調製した。噴霧液を噴霧乾燥し乾燥後、本発明の経口投与用医薬組成物(固体分散体)を得た。
表1の処方に従って、化合物A 0.5 g、ヒドロキシプロピルセルロース(HPC-SL、日本曹達製、以下記載無い場合同じ)1.5 gを、ジクロロメタンとメタノールとの混液に溶解し噴霧液を調製した。噴霧液を噴霧乾燥し乾燥後、本発明の経口投与用医薬組成物(固体分散体)を得た。
表1の処方に従って、化合物A 0.5 g、ポリビニルピロリドン(Kollidon30、BASF製)1.5 gを、ジクロロメタンとメタノールとの混液に溶解し噴霧液を調製した。噴霧液を噴霧乾燥し乾燥後、比較用の経口投与用医薬組成物(固体分散体)を得た。
(1)固体分散体の調製
化合物A 250.0 g、ヒドロキシプロピルセルロース 87.5 gを、ジクロロメタンとメタノールとの混液に溶解し噴霧液を調製した。噴霧液を噴霧乾燥し乾燥後、本発明の経口投与用医薬組成物(固体分散体)を得た。
(1)で製造した固体分散体 1350 mg、炭酸水素ナトリウム(炭酸水素ナトリウム、Merck製、以下記載無い場合同じ)1500 mg、結晶セルロース(セオラスPH-101、旭化成ケミカルズ製、以下記載無い場合同じ)3075 mg、デンプングリコール酸ナトリウム(Primojel、DMV-Fonterra製、以下記載無い場合同じ)1500 mg、ステアリン酸マグネシウム(Parteck(登録商標) LUB MST、MERCK製、以下記載無い場合同じ)75 mgを混合した。前記混合物 750 mgを圧縮成形して本発明の経口投与用医薬組成物(錠剤)を得た。処方を表1に示す。
(1)固体分散体の調製
化合物A 1200 g、ヒドロキシプロピルセルロース 420 gを、ジクロロメタンとメタノールとの混液に溶解し噴霧液を調製した。噴霧液を噴霧乾燥し乾燥後、本発明の経口投与用医薬組成物(固体分散体)を得た。
(1)で製造した固体分散体 1350 mg、炭酸水素ナトリウム 1500 mg、結晶セルロース 3131.25 mg、デンプングリコール酸ナトリウム 1500 mg、ステアリン酸マグネシウム 18.75 mgを混合した。前記混合物750 mgを圧縮成形して本発明の経口投与用医薬組成物(錠剤)を得た。処方を表1に示す。
実施例3(1)で製造した固体分散体 675 mg、炭酸水素ナトリウム 375 mg、結晶セルロース 1912.5 mg、デンプングリコール酸ナトリウム 750 mg、ステアリン酸マグネシウム 37.5 mgを混合し、そのうち750 mgを秤量して圧縮成形を行い、本発明の経口投与用医薬組成物(錠剤)を得た。処方を表1に示す。
実施例3(1)で製造した固体分散体 675 mg、炭酸水素ナトリウム 187.5 mg、結晶セルロース 2100 mg、デンプングリコール酸ナトリウム 750 mg、ステアリン酸マグネシウム 37.5 mgを混合し、そのうち750 mgを秤量して圧縮成形を行い、本発明の経口投与用医薬組成物(錠剤)を得た。処方を表2に示す。
実施例3(1)で製造した固体分散体 675 mg、炭酸水素ナトリウム 750 mg、リン酸水素カルシウム水和物(リカ、協和化学工業製)1537.5 mg、デンプングリコール酸ナトリウム 750 mg、ステアリン酸マグネシウム 37.5 mgを混合し、そのうち750 mgを秤量して圧縮成形を行い、本発明の経口投与用医薬組成物(錠剤)を得た。処方を表2に示す。
実施例4(1)で製造した固体分散体 1350 mg、炭酸水素ナトリウム 1500 mg、結晶セルロース 3131.25 mg、低置換度ヒドロキシプロピルセルロース(L-HPC LH11、信越化学工業製)1500 mg、ステアリン酸マグネシウム 18.75 mgを混合し、そのうち750 mgを秤量して圧縮成形を行い、本発明の経口投与用医薬組成物(錠剤)を得た。処方を表2に示す。
実施例4(1)で製造した固体分散体 2700 mg、炭酸水素ナトリウム 3000 mg、結晶セルロース 6262.5 mg、クロスカルメロースナトリウム(キッコレートND-2HS、ニチリン化学製)3000 mg、ステアリン酸マグネシウム 37.5 mgを混合し、そのうち750 mgを秤量して圧縮成形を行い、本発明の経口投与用医薬組成物(錠剤)を得た。処方を表2に示す。
(1)固体分散体の調製
化合物A 2.0 kg、ヒドロキシプロピルセルロース 0.7 kgを、ジクロロメタンとメタノールとの混液に溶解し噴霧液を調製した。噴霧液を噴霧乾燥し乾燥後、本発明の経口投与用医薬組成物(固体分散体)を得た。
(1)で製造した固体分散体 2700 g、炭酸水素ナトリウム 3000 g、結晶セルロース 6262.5 g、デンプングリコール酸ナトリウム 3000 gを混合し、乾式造粒を行った。その後ステアリン酸マグネシウム 37.5 gを混合し、圧縮成形を行った。その後、フィルムコート剤(OPADRY、カラコン製、以下記載ない場合同じ)450 gをフィルムコートし、本発明の経口投与用医薬組成物(錠剤)を得た。処方を表2に示す。
実施例10(1)と同様の条件で製造した固体分散体 378.0 g、炭酸水素ナトリウム 420.0 g、結晶セルロース 876.75 g、デンプングリコール酸ナトリウム 420.0 gを混合し、乾式造粒を行った。その後ステアリン酸マグネシウム 5.25 gを混合し,圧縮成形を行った。その後、フィルムコート剤 63 gをフィルムコートし、本発明の経口投与用医薬組成物(錠剤)を得た。処方を表2に示す。
実施例4(1)で製造した固体分散体 2700 mg、炭酸水素ナトリウム 750 mg、結晶セルロース 8512.5 mg、クロスカルメロースナトリウム 3000 mg、ステアリン酸マグネシウム37.5 mgを混合し、そのうち750 mgを秤量して圧縮成形を行い、本発明の経口投与用医薬組成物(錠剤)を得た。処方を表3に示す。
実施例4(1)で製造した固体分散体 1350 mg、炭酸水素ナトリウム 750 mg、結晶セルロース 4256.25 mg、クロスカルメロースナトリウム 1125 mg、ステアリン酸マグネシウム18.75 mgを混合し、そのうち750 mgを秤量して圧縮成形を行い、本発明の経口投与用医薬組成物(錠剤)を得た。処方を表3に示す。
実施例4(1)で製造した固体分散体 2700 mg、炭酸水素ナトリウム 1500 mg、結晶セルロース 7762.5 mg、クロスカルメロースナトリウム 3000 mg、ステアリン酸マグネシウム37.5 mgを混合し、そのうち750 mgを秤量して圧縮成形を行い、本発明の経口投与用医薬組成物(錠剤)を得た。処方を表3に示す。
実施例4(1)で製造した固体分散体 1350 mg、炭酸水素ナトリウム 937.5 mg、結晶セルロース 4256.25 mg、クロスカルメロースナトリウム 937.5 mg、ステアリン酸マグネシウム18.75 mgを混合し、そのうち750 mgを秤量して圧縮成形を行い、本発明の経口投与用医薬組成物(錠剤)を得た。処方を表3に示す。
実施例4(1)で製造した固体分散体 1350 mg、炭酸水素ナトリウム1125 mg、結晶セルロース 4256.25 mg、クロスカルメロースナトリウム 750 mg、ステアリン酸マグネシウム18.75 mgを混合し、そのうち750 mgを秤量して圧縮成形を行い、本発明の経口投与用医薬組成物(錠剤)を得た。処方を表3に示す。
実施例4(1)で製造した固体分散体 1350 mg、炭酸水素ナトリウム 1125 mg、結晶セルロース 3881.25 mg、クロスカルメロースナトリウム 1125 mg、ステアリン酸マグネシウム18.75 mgを混合し、そのうち750 mgを秤量して圧縮成形を行い、本発明の経口投与用医薬組成物(錠剤)を得た。処方を表3に示す。
実施例4(1)で製造した固体分散体 2700 mg、炭酸水素ナトリウム 3000 mg、結晶セルロース 8512.5 mg、クロスカルメロースナトリウム 750 mg、ステアリン酸マグネシウム37.5 mgを混合し、そのうち750 mgを秤量して圧縮成形を行い、本発明の経口投与用医薬組成物(錠剤)を得た。処方を表3に示す。
実施例4(1)で製造した固体分散体 2700 mg、炭酸水素ナトリウム 3000 mg、結晶セルロース 7762.5 mg、クロスカルメロースナトリウム 1500 mg、ステアリン酸マグネシウム37.5 mgを混合し、そのうち750 mgを秤量して圧縮成形を行い、本発明の経口投与用医薬組成物(錠剤)を得た。処方を表3に示す。
実施例4(1)で製造した固体分散体 2700 mg、炭酸水素ナトリウム 4500 mg、結晶セルロース 7012.5 mg、クロスカルメロースナトリウム 750 mg、ステアリン酸マグネシウム37.5 mgを混合し、そのうち750 mgを秤量して圧縮成形を行い、本発明の経口投与用医薬組成物(錠剤)を得た。処方を表3に示す。
実施例4(1)で製造した固体分散体2700 mg、炭酸水素ナトリウム750 mg、結晶セルロース 10012.5 mg、クロスカルメロースナトリウム1500 mg、ステアリン酸マグネシウム37.5 mgを混合し、そのうち750 mgを秤量して圧縮成形を行い、本発明の経口投与用医薬組成物(錠剤)を得た。処方を表3に示す。
実施例4(1)で製造した固体分散体2700 mg、炭酸水素ナトリウム1500 mg、結晶セルロース9262.5 mg、クロスカルメロースナトリウム1500mg、ステアリン酸マグネシウム37.5mgを混合し、そのうち750 mgを秤量して圧縮成形を行い、本発明の経口投与用医薬組成物(錠剤)を得た。処方を表3に示す。
実施例1、2、比較例1の経口投与用医薬組成物(固体分散体)664 mgを量り、水を加えて懸濁させ、1.33 mg/mLの懸濁液とした。このサンプルを調製直後に溶出試験を行い評価した。溶出試験条件としてJP2、250 mLとし、パドル法 50 rpmで、紫外分光法(UV法(測定波長:348 nm))により試験を行った。
結果を図1~3に示す。ポリビニルピロリドンを用いた固体分散体(図3、比較例1)は60分以降に溶出率の低下が認められたのに対し、ヒプロメロースを用いた固体分散体(図1、実施例1)またはヒドロキシプロピルセルロースを用いた固体分散体(図2、実施例2)においては過飽和状態を維持した。
実施例3~11の経口投与用医薬組成物(錠剤)について、日本薬局方溶出試験パドル法(25 rpm)に従って溶出率測定を実施した。試験液は 0.03 規定 塩酸 900 mLを用い、紫外分光法(UV法(測定波長:343 nm))により測定した。結果を図4に示す。何れの医薬組成物も結晶原薬を含む医薬組成物より溶出性を改善した。
実施例4、実施例8、実施例9の経口投与用医薬組成物(錠剤)をアルミ袋に入れ、密封したまま、70℃で7日間保存した。保存前後の類縁物質測定をHPLC法で行った。
なお、類縁物質測定は、以下の条件で行った:
・HPLCカラムとして、Inertsil C8-3、粒子径3 μm、4.6 mm(内径)×15 cm(GL Sciences製)又はその同等品を使用し、40℃付近の一定温度に維持した。
・移動相Aとして、pH 2.0 過塩素酸溶液を用いた。
・移動相Bとして、アセトニトリルを用いた。
・抽出液はアセトニトリル/水混液(7:3)を用いた。
・試料溶液は、化合物Aの濃度が200 μg/mLとなるように、抽出液で希釈したものを用いた。
・以下の表4に示すグラジエントプログラムにて紫外吸光光度計(波長:210 nm)で類縁物質測定を行い、化合物A及びその類縁物質の総ピーク面積に対する百分率として、それぞれの類縁物質のピーク面積の百分率を計算した。
実施例8、9の本発明の経口投与用医薬組成物を25℃ 75%RH開放条件にて6日間保存した。保存前後の溶出性を、日本薬局方溶出試験パドル法(50 rpm)に従って評価した。試験液は 0.03 規定 塩酸 900 mLを用い、試験開始後30分後における化合物Aの溶出率を紫外分光法(UV法(測定波長:343 nm))により測定した。結果を表6に示す。実施例8、9の医薬組成物は、化合物Aの溶出率の変化を抑制することができた。
実施例12~22の本発明の経口投与用医薬組成物を25℃ 75%RH開放条件にて6日間保存した。保存前後の溶出性を、日本薬局方溶出試験パドル法(50 rpm)に従って評価した。試験液は 0.03 規定 塩酸 900 mLを用い、試験開始後15分後における化合物Aの溶出率を紫外分光法(UV法(測定波長:343 nm))により測定した。結果を表7に示す。実施例12~22の医薬組成物は、化合物Aの溶出率の変化を抑制することができた。
化合物A 50 g、ヒドロキシプロピルセルロース 15 gを、ジクロロメタンとメタノールとの混液に溶解し噴霧液を調製した。噴霧液を噴霧乾燥し乾燥後、本発明の経口投与用医薬組成物(固体分散体)を得た。
化合物A 500 g、ヒドロキシプロピルセルロース500 gを、ジクロロメタンとメタノールとの混液に溶解し噴霧液を調製した。噴霧液を噴霧乾燥し乾燥後、本発明の経口投与用医薬組成物(固体分散体)を得た。
化合物A 50 g、ヒプロメロース25 gを、ジクロロメタンとメタノールとの混液に溶解し噴霧液を調製した。噴霧液を噴霧乾燥し乾燥後、本発明の経口投与用医薬組成物(固体分散体)を得た。
実施例23~25で得られた医薬組成物(固体分散体)を化合物A 100 mg、又は500 mg相当量をそれぞれ雄性ビーグル犬に絶食下経口投与した。投与後、経時的に採血し遠心分離により得られた血漿中化合物A濃度を測定した。なお、イヌは投与予定時刻から16時間以上前から絶食とした。また、投与前30分、投与後30分及び90分にペンタガストリンを臀部に筋肉内投与し、胃内pHを酸性にして試験を実施した。化合物A 100 mgを含む医薬組成物の、経口投与後の時間から24時間までの血漿中濃度時間曲線下面積(AUC0-24h)を1.00としたときの、化合物A 500 mgを含む医薬組成物のAUC0-24hを「AUC0-24h (GMR)」として算出した。結果を表8に示す。
その結果、特に実施例23、24の医薬組成物(固体分散体)は、良好な用量比例性を有していることが分かった。
以上、本発明を特定の態様に沿って説明したが、当業者に自明の変形や改良は本発明の範囲に含まれる。
Claims (15)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2017013896A MX2017013896A (es) | 2015-04-28 | 2016-04-27 | Composicion farmaceutica para administracion oral. |
EP16786506.2A EP3290037A4 (en) | 2015-04-28 | 2016-04-27 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION |
CN201680024436.1A CN107530342A (zh) | 2015-04-28 | 2016-04-27 | 口服给药用医药组合物 |
JP2017515569A JP6680297B2 (ja) | 2015-04-28 | 2016-04-27 | 経口投与用医薬組成物 |
US15/569,682 US10583087B2 (en) | 2015-04-28 | 2016-04-27 | Pharmaceutical composition for oral administration |
PH12017501831A PH12017501831A1 (en) | 2015-04-28 | 2017-10-06 | Pharmaceutical compositions for oral administration |
HK18105083.7A HK1245646A1 (zh) | 2015-04-28 | 2018-04-19 | 口服給藥用醫藥組合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015092005 | 2015-04-28 | ||
JP2015-092005 | 2015-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016175230A1 true WO2016175230A1 (ja) | 2016-11-03 |
Family
ID=57198463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/063151 WO2016175230A1 (ja) | 2015-04-28 | 2016-04-27 | 経口投与用医薬組成物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US10583087B2 (ja) |
EP (1) | EP3290037A4 (ja) |
JP (1) | JP6680297B2 (ja) |
CN (1) | CN107530342A (ja) |
HK (1) | HK1245646A1 (ja) |
MX (1) | MX2017013896A (ja) |
PH (1) | PH12017501831A1 (ja) |
TW (1) | TW201713343A (ja) |
WO (1) | WO2016175230A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019172420A1 (ja) * | 2018-03-09 | 2019-09-12 | 協和発酵キリン株式会社 | 医薬組成物 |
WO2020122244A1 (ja) * | 2018-12-14 | 2020-06-18 | 富士フイルム株式会社 | 錠剤及びその製造方法 |
WO2022004859A1 (ja) * | 2020-07-02 | 2022-01-06 | ARTham Therapeutics株式会社 | 経口用医薬組成物及びその製造方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998029137A1 (fr) * | 1996-12-25 | 1998-07-09 | Yamanouchi Pharmaceutical Co., Ltd. | Compositions medicinales immediatement desintegrables |
WO2014133056A1 (ja) * | 2013-02-28 | 2014-09-04 | アステラス製薬株式会社 | 2-アシルアミノチアゾール誘導体またはその塩 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101047042B1 (ko) | 2004-11-23 | 2011-07-06 | 동화약품주식회사 | 생체이용율을 향상시킨 경구용 제제 |
JP2009514884A (ja) | 2005-11-04 | 2009-04-09 | イーストマン ケミカル カンパニー | 難溶性医薬活性剤の投与のためのカルボキシアルキルセルロースエステル |
BRPI0818161B8 (pt) * | 2007-10-12 | 2021-05-25 | Novartis Ag | mistura estável compreendendo agonista de receptores de s1p, sua forma de dosagem final e seu uso |
PT2593081E (pt) * | 2010-07-15 | 2014-06-11 | Tedec Meiji Farma S A | Composição de comprimido à base de ferrimanitol ovalbumina |
TWI564008B (zh) | 2010-09-30 | 2017-01-01 | 鹽野義製藥股份有限公司 | 難溶性藥物之溶解性改善製劑 |
-
2016
- 2016-04-27 CN CN201680024436.1A patent/CN107530342A/zh active Pending
- 2016-04-27 EP EP16786506.2A patent/EP3290037A4/en not_active Withdrawn
- 2016-04-27 US US15/569,682 patent/US10583087B2/en not_active Expired - Fee Related
- 2016-04-27 JP JP2017515569A patent/JP6680297B2/ja not_active Expired - Fee Related
- 2016-04-27 MX MX2017013896A patent/MX2017013896A/es unknown
- 2016-04-27 TW TW105113125A patent/TW201713343A/zh unknown
- 2016-04-27 WO PCT/JP2016/063151 patent/WO2016175230A1/ja active Application Filing
-
2017
- 2017-10-06 PH PH12017501831A patent/PH12017501831A1/en unknown
-
2018
- 2018-04-19 HK HK18105083.7A patent/HK1245646A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998029137A1 (fr) * | 1996-12-25 | 1998-07-09 | Yamanouchi Pharmaceutical Co., Ltd. | Compositions medicinales immediatement desintegrables |
WO2014133056A1 (ja) * | 2013-02-28 | 2014-09-04 | アステラス製薬株式会社 | 2-アシルアミノチアゾール誘導体またはその塩 |
Non-Patent Citations (7)
Title |
---|
BEAK, IN-HWAN ET AL.: "Improved Supersaturation and Oral Absorption of Dutasteride by Amorphous Solid Dispersions", CHEM. PHARM. BULL., vol. 60, no. 11, 2012, pages 1468 - 1473, XP055161211, ISSN: 0009-2363 * |
DATABASE REGISTRY September 2014 (2014-09-01), XP055494705, retrieved from STN Database accession no. 1624297- 26-2 * |
HAJIME KONNO ET AL.: "Stabilization Effect of Polymers on Solid Dispersions against Crystallization", JOURNAL OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY, vol. 71, no. 2, 2011, Japan, pages 109 - 113, XP009506964, ISSN: 2188-3149 * |
KAJIYAMA, ATSUSHI ET AL.: "Improvement of HPMC Tablet Disintegration by the Addition of Inorganic Salts", CHEM. PHARM. BULL., vol. 56, no. 4, 2008, pages 598 - 601, XP055327107, ISSN: 0009-2363 * |
KUMPRAKOB, USANEE ET AL.: "Permeation Enhancement of Ketoprofen Using a Supersaturated System with Antinucleant Polymers", BIOL. PHARM. BULL., vol. 28, no. 9, 2005, pages 1684 - 1688, XP055327110, ISSN: 1347-5215 * |
See also references of EP3290037A4 * |
SUZUKI, HIDESHI ET AL.: "Influence of Water- Soluble Polymers on the Dissolution of Nifedipine Solid Dispersions with Combined Carriers", CHEM. PHARM. BULL., vol. 46, no. 3, 1998, pages 482 - 487, XP000748996, ISSN: 0009-2363 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019172420A1 (ja) * | 2018-03-09 | 2019-09-12 | 協和発酵キリン株式会社 | 医薬組成物 |
WO2020122244A1 (ja) * | 2018-12-14 | 2020-06-18 | 富士フイルム株式会社 | 錠剤及びその製造方法 |
WO2022004859A1 (ja) * | 2020-07-02 | 2022-01-06 | ARTham Therapeutics株式会社 | 経口用医薬組成物及びその製造方法 |
JPWO2022004859A1 (ja) * | 2020-07-02 | 2022-01-06 | ||
JP7149449B2 (ja) | 2020-07-02 | 2022-10-06 | ARTham Therapeutics株式会社 | 経口用医薬組成物及びその製造方法 |
CN115989022A (zh) * | 2020-07-02 | 2023-04-18 | 阿瑟姆治疗株式会社 | 口服用药物组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2016175230A1 (ja) | 2018-02-22 |
EP3290037A4 (en) | 2019-01-23 |
JP6680297B2 (ja) | 2020-04-15 |
TW201713343A (zh) | 2017-04-16 |
EP3290037A1 (en) | 2018-03-07 |
HK1245646A1 (zh) | 2018-08-31 |
MX2017013896A (es) | 2018-03-15 |
US10583087B2 (en) | 2020-03-10 |
CN107530342A (zh) | 2018-01-02 |
PH12017501831A1 (en) | 2018-04-23 |
US20180116965A1 (en) | 2018-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6531153B2 (en) | Composition with sustained release of levodopa and carbidopa | |
JP5289975B2 (ja) | マンニトール又は乳糖を含有する固形製剤 | |
WO2017140254A1 (zh) | 一种含有jak激酶抑制剂或其可药用盐的药物组合物 | |
WO2020249001A1 (zh) | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 | |
JP2016166230A (ja) | ナルブフィンを含有する製剤及びそれらの使用 | |
JP7172997B2 (ja) | エンザルタミドを含有する経口投与用医薬組成物 | |
JP2014224079A (ja) | 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠 | |
WO2016175230A1 (ja) | 経口投与用医薬組成物 | |
JPWO2008072533A1 (ja) | 固形製剤の製造方法 | |
JP2009521518A (ja) | 無水オランザピンi型の経口処方物 | |
CA3157788A1 (en) | Oral pharmaceutical composition comprising carbamate compound and preparation method therefor | |
JP5823592B2 (ja) | 安定性が改善された製剤 | |
JP7355020B2 (ja) | 経口投与用医薬組成物 | |
JP4999297B2 (ja) | 高含量塩酸テルビナフィン小型錠剤 | |
WO2020111089A1 (ja) | 医薬組成物 | |
JP2011037767A (ja) | 薬物および噴霧乾燥粒子を含有する口腔内速崩壊錠 | |
JP2006510665A (ja) | 新規な経口即時放出型投与剤形 | |
US9775832B2 (en) | Pharmaceutical composition for oral administration | |
JP5900702B2 (ja) | 経口投与用医薬組成物 | |
JP2014070061A (ja) | シクロデキストリンとの混合体を含有する錠剤 | |
JP3934150B1 (ja) | 固形製剤および製剤組成物 | |
JP2021008444A (ja) | メトトレキサートを含むフィルムコーティング錠 | |
JP2007169264A (ja) | 固形製剤および製剤組成物 | |
JP2020015690A (ja) | レボセチリジン含有錠剤 | |
JP2015212244A (ja) | ロピニロール塩酸塩を含有する口腔内崩壊錠 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16786506 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017515569 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12017501831 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15569682 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2017/013896 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |